AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 1 - (NewsRx.com & NewsRx.net) -- A growing body of data demonstrating the ability of HPV (human papillomavirus) testing to identify women at high risk of cervical cancer more accurately than the most advanced type of Pap test was presented at an international medical conference in Mexico City, announced Digene Corp. (DIGE).
In recognition of these research findings, some experts are recommending that the HPV test replace the Pap as the first-line tool for cervical cancer screening, particularly in low-resource countries in the developing world.
Speaking as an invited lecturer at the 21st Annual Papillomavirus Conference & Clinical Workshop, professor Jack Cuzick, PhD, head of epidemiology for Cancer Research U.K. at Queen Mary's College in London, said: "The general principal is that screening should be performed as infrequently as possible using the best available test. There is no doubt that the HPV DNA test is more sensitive than cytology (Pap testing). This has been shown in every study conducted, using both conventional and liquid-based cytology."
Cuzick concluded that the available evidence supports a recommendation that the high-risk HPV DNA test be used as the primary tool for cervical cancer screening, with the Pap performed only in women who test positive for the human papillomavirus - which causes virtually all cases of cervical cancer. To further research this proposal, he announced he is planning a European primary-screening study involving one million women.
Digene's DNAwithPap Test is the only test for high-risk types of HPV approved by the U.S. Food and Drug Administration (FDA). It is approved in the United States for use in conjunction with the Pap test in women age 30 and older, as well as for follow-up evaluation in women whose Pap results are uncertain.
In a ...